Editorial

As we embark on the first issue of Volume 2 of Prostate Cancer and Prostatic Diseases (PCPD), we are proud to announce that the Journal has been accepted into Current Contents/Clinical Medicine, an almost unprecedented step after only 18 months of publication. This is a tribute to the hard work of the editorial team and the quality of papers we have published. We obviously need to maintain our very high standards.

PCPD is now available in its entirety on the web, and at the same subscription rate as the printed version. The combined print/online version is also available for a small extra charge. So much information about prostate cancer is already available on the web, but much of it is unsubstantiated and not subject to peer review. The advent of PCPD on the web, as well as other urology journals, should help to counterbalance this.

This issue contains an outstanding review on familial prostate cancer, together with excellent papers on gene

therapy, new chemotherapeutic approaches to prostate cancer, transurethral electrovaporisation of the prostate, eight-year pathological results of radical prostatectomy and a meta-analysis of maximum androgen blockade with flutamide in prostate cancer. Each and every one of these papers is of a high scientific standard yet directly relevant to the practising clinician.

We are delighted by the level of support the journal is receiving internationally and look forward in 1999 to publishing new and exciting developments in the understanding and treatment of prostatic diseases.

Roger Kirby

Howard Sher

Michael Brawer